All In Biotech

Drug Trial Radar · NCT06947291

Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors

A Multicenter, Open-label, Phase II Clinical Study to Evaluate the Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors With MET Overexpression and/or Amplification

Last checked: Nov 20, 2026Latest source record: Sep 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 350 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

350

Planned (sponsor's estimate)

Start

Jun 4, 2025

Primary completion

Apr 30, 2027

Study completion Oct 30, 2027

Sponsor

Sponsor type
Industry
First posted
Apr 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The trial consists of Stage 1 (including dose escalation and dose expansion) and Stage 2 (proof-of-concept study). Among them, Stage 2 adopts a randomized, controlled, open-label, and multicenter design.

Conditions

  • Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors

Interventions

  • Glumetinib TabletsDrug

    glumetinib once daily once daily under fasting conditions in each 21-day treatment cycle.

  • Docetaxel for Injection (Albumin-bound)Drug

    Docetaxel for Injection (Albumin-bound) by intravenous injection in each 21-day treatment cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose escalation and cohort expansion phase: The occurrence and frequency of DLT (Dose-Limiting Toxicity)Time frame: Up to approximately 24 months after the first patient is enrolled
  2. Dose escalation and cohort expansion phase: the occurrence and frequency of AE (Adverse Events) and SAE (Serious Adverse Events) (in accordance with NCI-CTCAE 5.0)Time frame: Up to approximately 24 months after the first patient is enrolled
  3. Dose escalation and cohort expansion phase: Recommended Phase 2 Dose (RP2D) for the combination therapy.Time frame: Up to approximately 24 months after the first patient is enrolled
  4. Proof-of-concept phase: Objective Response Rate (ORR) evaluated by the Independent Review Committee (IRC) according to the RECIST 1.1 criteria.Time frame: Up to approximately 24 months after the first patient is enrolled

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.